In this CARTITUDE-4 subgroup analysis of patients treated with cilta-cel, what was observed for patients who achieved at least a partial response to bridging therapy?
Improved PFS and OS compared with bridging non-responders, but only in patients with standard-risk cytogenetics
Improved PFS and numerically longer OS compared with non-responders, in both standard-risk and high-risk cytogenetic groups, and no cases of parkinsonism
No difference in PFS or OS compared with non-responders, but fewer cases of CRS and neurotoxicity